Trevi Therapeutics presents CHEST data: BMO rates Trevi Therapeutics stock Outperform

Published on 10/16/2026 at 03:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

CHEST 2026 will feature CORAL results on October 20, 2026. A USD 36.00 target and Outperform rating apply to Trevi Therapeutics stock.

Clinical catalyst and valuation context

Trevi announced the CHEST presentation on October 13, 2026.
BMO retained a USD 36.00 target and Outperform rating on October 7, 2026.
Trevi's market capitalization was USD 1.7 billion as of October 15, 2026.

TRVI, US89532M1018, Illustration mit AI erstellt.

Trevi Therapeutics (ISIN US89532M1018) announced on October 13, 2026 that Phase 2b CORAL results would be presented at the CHEST 2026 Annual Meeting, giving its Haduvio program a dated clinical milestone. According to BioSpace, the presentation is scheduled for October 20, 2026, and will cover patient-reported outcomes from the trial.

Clinical data set the next date

The CHEST session concerns oral nalbuphine extended-release, Trevi's investigational therapy for chronic cough associated with idiopathic pulmonary fibrosis. The trial tested 27 mg, 54 mg and 108 mg doses twice daily against placebo over six weeks, according to BioSpace. The company is developing Haduvio across idiopathic pulmonary fibrosis, non-IPF interstitial lung disease and refractory chronic cough.

What does the cash position mean?

Trevi's second-quarter 2026 earnings per share came in at minus USD 0.11, compared with a consensus estimate of minus USD 0.10, while cash, cash equivalents and marketable securities totaled approximately USD 319 million. Investing.com reported on October 7, 2026 that BMO retained an Outperform rating and a USD 36.00 price target. The same report said the cash position was expected to fund operations until 2030.

October 20 presentation date

The next dated company event is the CHEST 2026 oral presentation on October 20, 2026. Separately, Trevi expects a sample-size re-estimation for its LAKE study in the fourth quarter of 2026, a development that could shape the company's clinical planning.

Market value reflects a clinical-stage profile

Trevi was last at USD 12.11 on Nasdaq on October 15, 2026 at 4:00 p.m. ET. Its market capitalization was USD 1.7 billion and its 52-week range was USD 9.82 to USD 20.22 as of October 15, 2026, placing the upcoming presentation alongside a stock trading well below its yearly high.